Cullinan Therapeutics (CGEM) Other financing activities (2020 - 2022)

Cullinan Therapeutics' Other financing activities history runs 3 years deep, the most recent figure standing at $1.2 million for Q1 2022.

• On a quarterly basis, Other financing activities fell 99.57% year-over-year to $1.2 million in Q1 2022; TTM through Dec 2022 was $1.2 million, a 24.92% increase from a year earlier, with the FY2022 full-year figure at $1.2 million, up 24.92% from the prior year.
• Other financing activities rose to $1.2 million in Q1 2022 per CGEM's latest filing, from -$266.3 million in the prior quarter.
• Across five years, Other financing activities topped out at $267.3 million in Q1 2021 and bottomed at -$266.3 million in Q2 2021.
• The 3-year median for Other financing activities is $1500.0 (2020), against an average of $231500.0.
• Biggest YoY gain for Other financing activities was 99.57% in 2022; the steepest drop was 99.57% in 2022.
• Year by year, Other financing activities stood at -$1.2 million in 2020, then slumped by 23060.43% to -$266.3 million in 2021, then surged by 100.43% to $1.2 million in 2022.
• Per Business Quant, the three latest CGEM Other financing activities figures stand at $1.2 million (Q1 2022), -$266.3 million (Q2 2021), and $267.3 million (Q1 2021).